Bellevue Group’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-212,559
Closed -$4.84M 166
2024
Q2
$4.84M Sell
212,559
-234,817
-52% -$5.42M 0.08% 96
2024
Q1
$13.6M Sell
447,376
-370,507
-45% -$12.4M 0.21% 88
2023
Q4
$29.2M Buy
817,883
+70,323
+9% +$2.62M 0.45% 64
2023
Q3
$32.7M Sell
747,560
-1,053
-0.1% -$51.4K 0.53% 53
2023
Q2
$37M Buy
748,613
+101,391
+16% +$4.67M 0.53% 59
2023
Q1
$26.8M Buy
647,222
+3,113
+0.5% +$129K 0.39% 69
2022
Q4
$28.6M Buy
644,109
+1,662
+0.3% +$69.4K 0.38% 71
2022
Q3
$25.1M Buy
642,447
+551
+0.1% +$25.2K 0.36% 74
2022
Q2
$26.2M Buy
641,896
+43,291
+7% +$2.05M 0.37% 74
2022
Q1
$39.3M Buy
598,605
+100,049
+20% +$6.48M 0.46% 68
2021
Q4
$34.7M Buy
498,556
+80,540
+19% +$5.85M 0.36% 79
2021
Q3
$29.1M Buy
418,016
+43,598
+12% +$3.36M 0.3% 92
2021
Q2
$29.7M Sell
374,418
-123,294
-25% -$8.96M 0.29% 93
2021
Q1
$32.6M Sell
497,712
-58,662
-11% -$3.61M 0.35% 85
2020
Q4
$31M Buy
+556,374
New +$24.1M 0.35% 77

Other funds holding ATRC

Bellevue Group's ATRC Position: Q3 2024 in Review

Bellevue Group sold out of AtriCure (ATRC) in Q3 2024, closing a stake of 212,559 shares — an estimated $4.84M sold.

Bellevue Group first reported a position in ATRC in Q4 2020 and held it in 15 quarters. The position peaked at $39.3M in Q1 2022. 201 funds tracked by Wall St. Rank hold ATRC as of Q3 2024.

  • Bellevue Group reported no remaining AtriCure position as of Q3 2024 after selling out during the quarter.
  • Bellevue Group sold 212,559 AtriCure shares in Q3 2024, an estimated $4.84M.
  • Bellevue Group first reported a position in AtriCure in Q4 2020 and held it in 15 quarters.
  • Bellevue Group's AtriCure position peaked at $39.3M in Q1 2022.
  • 201 funds tracked by Wall St. Rank held AtriCure as of Q3 2024.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.